sAXL, the cleaved extracellular domain of AXL, is being explored as a potential biomarker in certain cancers and other inflammatory conditions, such as in hepatocellular carcinoma, neurofibromatosis type 1, and in NSCLC [30–32, 77]. This evidence concerns the gene AXL and non-small cell lung carcinoma.